MedTrace Logo

Dynamic Evaluation of COVID-19 Diagnostic Tests

NCT04337996 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-01-26

No results posted yet for this study

Summary

Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been evaluated.

We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.

Conditions

Interventions

DIAGNOSTIC_TEST

COVID-19 diagnostic test

COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)

Sponsors & Collaborators

  • Tourcoing Hospital

    lead OTHER

Principal Investigators

  • Pierre PATOZ, PharmD · CH TOURCOING

  • Barthelemy LAFONDESMURS, MD · CH TOURCOING

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-13
Primary Completion
2021-01-13
Completion
2021-01-13

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04337996 on ClinicalTrials.gov